Proclaim Plus News Today

The global neurostimulation devices market is experiencing substantial growth, driven by advancements in technology and an increasing prevalence of neurological disorders. The market size is projected to expand from USD 11.1 billion in 2022 to USD 36.5 billion by 2032, growing at a compound annual growth rate (CAGR)...

A Bluetooth connectivity flaw has disabled Abbott implantable pulse generators (IPGs), requiring surgery to remove and replace them.

FDA has issued a Class I recall of 155,028 Abbott Medical implantable neurostimulation systems due to an inability to exit MRI mode, potentially leading to seri

Newark, New Castle, USA, July 04, 2023 (GLOBE NEWSWIRE) -- According to the recent analysis conducted by Growth Plus Reports, the global peripheral nerve...

Abbott has announced the FDA expanded the indication of its BurstDR spinal cord stimulation devices for treating chronic back pain in those who have not had or are ineligible for back surgery.

The U.S. Food and Drug Administration (FDA) approved Abbott's Eterna spinal cord stimulation (SCS) system for the treatment of chronic painThis neuromodulation device provides an optimized experience with

The Consumer Technology Association (CTA) awards Abbott multiple CES 2023 Innovation Awards for industry-leading health technologiesAbbott's Aveir single-chamber (VR) leadless pacemaker, Proclaim Plus

Abbott especially benefitted from the U.S. launch of the next-gen FreeStyle Libre 3 14-day CGM after FDA clearance in May.

EDINA, Minn., Sept. 29, 2022 (PRWEB) October 03, 2022 -- Twin Cities Pain Clinic announced it is integrating the new Proclaim™ Plus spinal cord stimulation

/PRNewswire/ -- Pain Specialists of America (PSA) announced it is integrating the new Proclaim™ Plus spinal cord stimulation (SCS) system featuring...